#PAT #GROWTH
In FY23, PAT was ₹888 cr, a decline of 19% YoY. This was due to exceptional gain of ₹294 cr in Q1 FY22. PAT growth was also impacted by lower operating profit.In 9M FY24, PAT was ₹668 cr, a decline of10% YoY. Profit during the period was impacted mainly due to higher finance and tax costs. the pick up in primary and secondary patient care, elective surgeries, addition of laboratories & collection centers in the diagnostic business coupled with focus on private label sales is likely to drive earnings growth.
In FY23, PAT was ₹888 cr, a decline of 19% YoY. This was due to exceptional gain of ₹294 cr in Q1 FY22. PAT growth was also impacted by lower operating profit.In 9M FY24, PAT was ₹668 cr, a decline of10% YoY. Profit during the period was impacted mainly due to higher finance and tax costs. the pick up in primary and secondary patient care, elective surgeries, addition of laboratories & collection centers in the diagnostic business coupled with focus on private label sales is likely to drive earnings growth.
👍7
#EBITDA #MARGIN
In FY23, EBITDA margin was 12.34%, a contraction of a 256 bps YoY. In 9M FY24, EBITDA margin was 12.4%, a contraction of 28 bps YoY. The margin was impacted due to the reduced share of elective and surgical revenue in the revenue mix due to the holiday and festive season, as well as investments in clinical talent, which is yet to be fully optimized.further increasing occupancy rate, payor mix, case mix and cost optimisation efforts are likely to aid in margin growth. However, this may be partially offset by the increased investment in Apollo 24/7 coupled with non cash expense arising out of ESOP charge which will continue for the next three years.
In FY23, EBITDA margin was 12.34%, a contraction of a 256 bps YoY. In 9M FY24, EBITDA margin was 12.4%, a contraction of 28 bps YoY. The margin was impacted due to the reduced share of elective and surgical revenue in the revenue mix due to the holiday and festive season, as well as investments in clinical talent, which is yet to be fully optimized.further increasing occupancy rate, payor mix, case mix and cost optimisation efforts are likely to aid in margin growth. However, this may be partially offset by the increased investment in Apollo 24/7 coupled with non cash expense arising out of ESOP charge which will continue for the next three years.
👍6
#ROCE
In FY23, ROCE was 17.78%. The moderation in operating profitability had a bearing on the metric.
In FY23, ROCE was 17.78%. The moderation in operating profitability had a bearing on the metric.
⚡5👍5😱1
#ROE
Apolo Hospitals Enterprise Ltd. ROE was 15.16%. This moderation can be attributed to a higher base from the previous year, which was supported by exceptional gain of ₹294 cr
Apolo Hospitals Enterprise Ltd. ROE was 15.16%. This moderation can be attributed to a higher base from the previous year, which was supported by exceptional gain of ₹294 cr
👍9
#Management #Outlook
Apollo Health Co will leverage Keimed's vast network of more than 70,000 stores to accelerate its ₹1,500 cr private label portfolio. The combined entity is likely to generate revenue of ₹25,000 cr in 3 years with 7%-8% of EBITDA margin.
Apollo Health Co will leverage Keimed's vast network of more than 70,000 stores to accelerate its ₹1,500 cr private label portfolio. The combined entity is likely to generate revenue of ₹25,000 cr in 3 years with 7%-8% of EBITDA margin.
👍13
Companies Manufacture Drones in India
I) Government-Owned Giants
1️⃣ HAL
II) Military Drone Leaders
1️⃣ L&T
2️⃣ Zen Technologies
3️⃣ DCM Shriram
III) Commercial Drone Service Providers
1️⃣ Info Edge
2️⃣ Drone Destination
3️⃣ Droneacharya
4️⃣ Rattanindia Enterprises
IV) Drone Technologies
1️⃣ Paras Defence
2️⃣ Bharat Forge
I) Government-Owned Giants
1️⃣ HAL
II) Military Drone Leaders
1️⃣ L&T
2️⃣ Zen Technologies
3️⃣ DCM Shriram
III) Commercial Drone Service Providers
1️⃣ Info Edge
2️⃣ Drone Destination
3️⃣ Droneacharya
4️⃣ Rattanindia Enterprises
IV) Drone Technologies
1️⃣ Paras Defence
2️⃣ Bharat Forge
👍29❤5
BIGGEST INTRADAY FALL IN NIFTY
May 2004:-18.33%
Oct 2012: -15.54%
Jan 2008:-14.59%
Oct 2008:-14.20%
March 2020:-13.30%
Oct 2008: -12.81%
Jan 2008:-12.76%
April 1992:-11.72%
May 1992:-11%
May 2006: -10.80%
May 2004:-18.33%
Oct 2012: -15.54%
Jan 2008:-14.59%
Oct 2008:-14.20%
March 2020:-13.30%
Oct 2008: -12.81%
Jan 2008:-12.76%
April 1992:-11.72%
May 1992:-11%
May 2006: -10.80%
😁19👍13🔥8❤4😱4
FMCG stocks index up 5%! 🔥
• Hindustan Unilever: +7.3%
• Dabur India: +7%
• United Breweries: +7%
• Godrej Consumer: +6.6%
• Britannia Industries: +6.5%
• Marico: +6.2%
• Colgate-Palmolive: +5.8%
• United Spirits: +5.8%
• Tata Consumer: +5.8%
• Nestle India: +4.8%
• Radico Khaitan: +4.4%
• ITC: +3.4%
• Balrampur Chini Mills: +2.8%
• Varun Beverages: +2.4%
• P&G Hygiene & Health Care: +1.2%
• Hindustan Unilever: +7.3%
• Dabur India: +7%
• United Breweries: +7%
• Godrej Consumer: +6.6%
• Britannia Industries: +6.5%
• Marico: +6.2%
• Colgate-Palmolive: +5.8%
• United Spirits: +5.8%
• Tata Consumer: +5.8%
• Nestle India: +4.8%
• Radico Khaitan: +4.4%
• ITC: +3.4%
• Balrampur Chini Mills: +2.8%
• Varun Beverages: +2.4%
• P&G Hygiene & Health Care: +1.2%
🔥17👍9